Arrowhead Pharmaceuticals, Inc. — Earnings Quality Grade F
ARWR · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue grew 23258.2% but CFFO only 138.8%
Expense Quality
No material inventory
CapEx growth -84.0% vs revenue 23258.2%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF $0.2B, FCF/NI = -96.19
Accruals ratio = -13.1%. Low accruals
Cash $0.9B covers debt $0.4B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 1% of equity. Manageable
Interest coverage = 1.1x (<2x). Financial stress
Other assets -69.0% vs revenue 23258.2%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
Goodwill+Intangibles change -20% YoY. Normal
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor ARWR continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25